文献速递治疗药物监测与药物基因组学特殊人群用药

ACCOuNT试验结果:针对非裔美国住院患者的多机构前瞻性药物基因组学实施试验

Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients.
PubMed 文献 · Clin Pharmacol Ther · 2025-08-22

ACCOuNT试验是一项多机构前瞻性研究,对非裔美国住院患者进行基因分型并通过药物基因组学临床决策支持(PGx CDS)系统提供结果以指导处方。共招募531例患者,187例再入院(60.4%女性,中位年龄55岁),产生518次可评估入院。50%的入院中医疗团队使用了PGx CDS,PGx CDS使用未减少基因组不一致处方(3.9% vs 3.3%,P=0.53),但团队频繁使用PGx CDS来确认基因组一致处方。

要点

  • 在非裔美国住院患者中,PGx CDS使用未显著降低基因组不一致处方(3.9% vs 3.3%,P=0.53)。
  • 48%的入院和91%的出院包含药物基因组学注释药物,多为基因组一致。
  • PGx CDS使用时机与处方时机高度相关(相关系数=0.84,P<0.05)。

核心结论

  • 在当前可操作的药物基因组学信息中,其指导住院患者处方的相关性有限,但医疗团队频繁使用PGx CDS来确认基因组一致处方。

研究设计与样本

  • 多机构前瞻性药物基因组学实施试验(ACCOuNT,NCT03225820),招募非裔美国住院患者进行基因分型并通过PGx CDS系统提供结果。
  • 共招募531例患者,其中187例再入院(60.4%女性,中位年龄55岁[范围19-88],中位再入院次数2次[范围1-17]),产生518次可评估入院。

主要发现

  • 50%的入院中医疗团队使用了PGx CDS。
  • 12%的住院处方有药物基因组学注释,仅3.6%与增加 caution 的药物基因组学相关(「不一致」),未处方PGx高风险药物。
  • PGx CDS使用未减少基因组不一致处方(3.9% vs 3.3%,P=0.53)。
  • 48%的入院和91%的出院包含药物基因组学注释药物,大多为基因组一致。
  • PGx CDS使用时机与处方时机高度相关(相关系数=0.84,P<0.05)。

临床怎么用

  • 在非裔美国住院患者中,PGx CDS可能更多用于确认基因组一致处方而非减少不一致处方。
  • 临床团队可参考PGx CDS在处方时机同步使用,以支持基因组一致用药决策。

局限性

  • 当前可操作的药物基因组学信息对住院处方的相关性有限。
  • 研究仅纳入非裔美国住院患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi-institutional prospective study [NCT03225820] in which African American inpatients were genotyped and pharmacogenomic results made available via an integrated, scalable pharmacogenomics clinical decision support (PGx CDS) system to guide prescribing. We hypothesized that PGx CDS utilization would improve genomically concordant prescribing during inpatient admissions. We recruited 531 patients, of which 187 were readmitted (60.4% female, median age = 55 [range: 19-88], median readmissions/patient = 2 [range: 1-17]), resulting in 518 evaluable admissions during which the effect of available pharmacogenomic results was measured. In 50% of admissions, care teams utilized PGx CDS. 12% of inpatient prescriptions had pharmacogenomic annotations, with only 3.6% pharmacogenomically associated with increased caution ("discordant"); no PGx high-risk medications were prescribed. PGx CDS use by provider teams did not decrease genomically discordant prescribing (3.9% vs. 3.3% without PGx CDS use, P = 0.53). Nevertheless, inpatient care teams repeatedly consulted PGx CDS ostensibly to affirm genomically concordant prescriptions, as 48% of all admissions and 91% of discharges included pharmacogenomically annotated medications, mostly genomically concordant. Notably, timing of PGx CDS utilization correlated tightly with prescribing timing (correlation coefficient = 0.84, P < 0.05). In the first results of a multi-institutional, prospective pharmacogenomics trial focused on underrepresented patients, we found the relevance of currently actionable pharmacogenomics information for guiding inpatient prescribing to be modest; but observed frequent use of concordant pharmacogenomics to affirm prescribing.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Huang Z, O'Leary KJ, Nutescu EA, et al. Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clin Pharmacol Ther. 2025. PMID: 40847467. doi:10.1002/cpt.70024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。